Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the timing of enrollment in clinical trials and the announcement of clinical results. Words such as "look forward," "suggests," "may," "expects," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Deerfield Management Company, L.P. ... Fund, L.P., which will invest in groundbreaking advancements in ... diseases, cancer, and orphan diseases. The venture capital fund ... therapeutics are developed and improve the way healthcare is ... the largest healthcare-focused venture funds in the sector, will ...
(Date:7/28/2015)... 2015  Moerae Matrix Inc. announced today the ... with MMI-0100, a first-in-class inhibitor of MAPKAP kinase ... disorders characterized by inflammation and fibrosis.  The study, ... , is a double-blind, two-way cross-over design lipopolysaccharide ... tolerability of MMI-0100 when given via inhalation to ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/28/2015)...  Faced with increasing challenges such as costly ... symptomatic, the global healthcare industry today is gradually ... curing or significantly changing the course of a ... regenerative medicine as a viable alternative. ... health with the potential to resolve unmet medical ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... , New kinase array designed for ... VANCOUVER , Feb. 10 /PRNewswire/ - ... novel Protein Kinase Microarray with 200 recombinant human protein ... applications for drug target counter screening, to identify novel ...
... ... pharmaceutical sales job seekers empowers users to search the most sought after jobs in the ... ... and pharmaceutical sales jobs on the web. But in a competitive market like medical ...
... ... 11-13, 2010 in Denver, CO. , ... Portland, ME (PRWEB) February 9, 2010 -- IntertechPira is pleased to ... Westin Tabor Center in Denver, CO, US. This year,s program will bring together ...
Cached Biology Technology:Kinexus Announces the Launch of a New Protein Kinase Microarray 2With the MedReps.com iPhone App, the Medical Sales Job Search Goes Mobile 2Dates Announced for IntertechPira's 5th Annual Biopolymers Symposium 2Dates Announced for IntertechPira's 5th Annual Biopolymers Symposium 3
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... , GAINESVILLE, FLA new trend shows native wildflowers are ... has experienced gains in popularity over the past 30 ... maturing, highly competitive market. In Florida, for example, a ... state totaled almost $316 million. College students do ...
... Alps, the Andes and the Himalayas in size yet surprisingly ... the world,s oceans. Now in a special issue of ... these submerged mountain ranges and reveal why these under studied ... our oceans is now resolved at a scale and detail ...
... University] Development of a potential treatment for the most ... phase at Brown University. Brown has granted an exclusive license ... that will strive to see it through human trials. ... (Monday, Sept. 20, 2010) to mark the start of this ...
Cached Biology News:College students want more information about native wildflowers 2Marine scientists unveil the mystery of life on undersea mountains 2Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals 2Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals 3
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... [EP282Y] to Asparagine synthetase ( ... applications). Antigen: ... residues in the C-terminus of ... Entrez GeneID: 440 ...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: